225 related articles for article (PubMed ID: 18088160)
1. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
[TBL] [Abstract][Full Text] [Related]
2. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
6. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
Sung AH; Marcella SW; Xie Y
J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
[TBL] [Abstract][Full Text] [Related]
7. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Lazzaro C
Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
Collins CD; Ellis JJ; Kaul DR
Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
11. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.
Grau S; de la Cámara R; Sabater FJ; Jarque I; Carreras E; Casado MA; Sanz MA
BMC Infect Dis; 2012 Apr; 12():83. PubMed ID: 22471553
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Dranitsaris G; Khoury H
Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
Wang J; Zhan P; Zhou R; Xu J; Shao X; Yang Y; Ouyang J
Med Oncol; 2010 Dec; 27(4):1082-8. PubMed ID: 19876778
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
[TBL] [Abstract][Full Text] [Related]
18. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
Papadopoulos G; Hunt S; Prasad M
J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
[TBL] [Abstract][Full Text] [Related]
20. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
